期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

晚期非小细胞肺癌的化疗与靶向治疗新进展 被引量：1

原文传递
导出
摘要 肺癌在很多国家已成为癌症死亡的首要疾病，多数患者诊断时已为晚期。晚期非小细胞肺癌（NSCLC）是指有远处转移的NSCLC，除少数单发脑转移或肾上腺转移的患者手术或放疗能延长患者生存期外，多数患者失去了根治手术与根治放疗的机会，治疗以化疗与靶向治疗为主。
作者 王孟昭 张力 钟巍 李龙芸
机构地区 中国医学科学院中国协和医科大学北京协和医院呼吸内科
出处 《中华内科杂志》 CAS CSCD 北大核心 2007年第8期691-694,共4页 Chinese Journal of Internal Medicine
关键词 晚期非小细胞肺癌 靶向治疗 化疗 根治手术 NSCLC 肾上腺转移 远处转移 生存期
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献20

  • 1Schiller JH, Haxrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med,2002,346:92-98.
  • 2Fossella F, Pereira JR, yon Pawel J, et al. Randomized, multinational, phase Ⅲ study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol, 2003,21:3016-3024.
  • 3Stathopoulos GP, Katis C, Tsavdaridis D, et al. Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase Ⅱ trial. Cancer Chemother Pharmacol,2006 ,58 :555-560.
  • 4Hoang T, Xu R, Schiller JH, et al. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol, 2005, 23:175-183.
  • 5Rosell R, Cobo M, Isla D, et al. Pharmacogenomics and gemcitabine. Ann Oncol, 2006,17 Suppl 5 : v13-v16.
  • 6IgnatiadisM, Kalbakis K, Vardakis N, et al. First line chemotherapy with docetaxel plus gemcitabine in elderly or poor performance status patients with advanced non-small cell lung cancer: the experience of the Hellenic Oncology Research Group (HORG). The 13th European Cancer Conference, Paris, 2005. http ://ex2. excerptamedica.com/ciw-05ecco/index. cfm.
  • 7O'Brien M, Oldham F. Paclitaxel poliglumex vs. gemcitabine or vinorelbine for the treatment of performance status (PS) 2 patients with chemotherapy-nai've advanced non-small cell lung cancer (NSCLC) : the STELLAR 4 phase Ⅲ study. The 13th European Cancer Conference, Paris, 2005. http ://ex2. excerptamedica. com/ciw-05 ecco/index.cfm.
  • 8Dancey J, Shepherd FA, Gralla R j, et al. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy : results of a prospective, randomized phase Ⅲ trial. Lung Cancer,2004,43 : 183-194.
  • 9Camps C, Massuti B, Jimenez A, et al. Randomized phase Ⅲ study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol,2006 ,17 :467-472.
  • 10Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol, 2004,22 : 1589-1597.

二级参考文献31

  • 1杨林,王金万,汤仲明,刘秀文,黄镜,李树婷,董英,张和平,薛岚,储大同,孙燕.重组人血管内皮抑制素Ⅰ期临床研究[J].中国新药杂志,2004,13(6):548-553. 被引量：154
  • 2周清华,孙燕.加强我国肺癌分子靶向治疗基础和临床研究[J].中国肺癌杂志,2004,7(4):267-269. 被引量：51
  • 3杨林,王金万,崔成旭,黄镜,张和平,李树亭,孙燕.重组人血管内皮抑制素YH-16联合用药治疗晚期非小细胞肺癌的多中心Ⅱ期临床试验[J].中国新药杂志,2005,14(2):204-207. 被引量：116
  • 4Folkman J. Role of angiogenesis in tumor growth and metastasis.Semin Oncol,2002,29(6 Suppl 16) : 15-18.
  • 5Huang X, Wong MK, Zhao Q, et al. Soluble recombinant endostatinpurified from Escherichia coli: antiangiogenic activity and antitumor effect. Cancer Res,2001,61(2): 478-481. Erratum in:Cancer Res, 2001,61 ( 15 ) : 5956. Cancer Res, 2001,61 (10) :4297.
  • 6Li B, Wu XY, Zhou H, et al. Acid-induced unfolding mechanism of recombinant human endostatin. Biochemistry, 2004, 43 (9) :2550-2557.
  • 7Eder JP Jr, Supko JG, Clark JW, et al. Phase Ⅰ clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol, 2002,20(18) : 3772-3784.
  • 8Kulke M, Bergsland E, Ryan DP, et al. A phase Ⅱ , open-label,safety, pharmacokinetic, and efficacy study of recombinant human endostatin in patients with advanced neuroendocrine tumors. Proc ASCO,2003,22: 958a.
  • 9Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase Ⅲ randomized trial comparing three platinum-based doublets in advanced nonsmall cell lung cancer. J Clin Oncol,2002,20(21) : 4285-4291.
  • 10Gebbia V, Galetta D, Caruso M, et al. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine fol lowed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage Ⅲ B-Ⅳ non small cell lung carcinoma: a prospective randomized phase Ⅲ trial of the Gruppo Oncologico Italia Meridionale. Lung Cancer,2003,39(2) :179-189.

共引文献625

同被引文献17

引证文献1

二级引证文献8

中华内科杂志
2007年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部